Who are LAR Lanreotide's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Signifor, Somatuline Depot, Sandostatin, Sandostatin LAR, Octreotide LAR, Sandostatin ® injection.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/lar-lanreotide.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

LAR Lanreotide — Competitive Intelligence Brief

LAR Lanreotide (LAR Lanreotide) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Somatostatin analog. Area: Oncology.

marketed Somatostatin analog Somatostatin receptors (SSTR2, SSTR5) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

LAR Lanreotide (LAR Lanreotide) — Memorial Sloan Kettering Cancer Center. Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
LAR Lanreotide TARGET	LAR Lanreotide	Memorial Sloan Kettering Cancer Center	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)
Signifor	PASIREOTIDE	Recordati	marketed	Somatostatin Analog [EPC]	Somatostatin receptor type 5	2012-01-01
Somatuline Depot	LANREOTIDE	Ipsen Pharma	marketed	Somatostatin Analog	Somatostatin receptor type 2	2007-01-01
Sandostatin	OCTREOTIDE	Novartis	marketed	Somatostatin Analog	Somatostatin receptor type 2	1988-01-01
Sandostatin LAR	Sandostatin LAR	Pfizer	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)
Octreotide LAR	Octreotide LAR	Cedars-Sinai Medical Center	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)
Sandostatin ® injection	Sandostatin ® injection	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.	marketed	Somatostatin analog	Somatostatin receptors (SSTR2, SSTR5)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Somatostatin analog class)

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · 1 drug in this class
Camurus AB · 1 drug in this class
Cedars-Sinai Medical Center · 1 drug in this class
Centre Hospitalier Universitaire, Amiens · 1 drug in this class
Debiovision · 1 drug in this class
Ipsen · 1 drug in this class
Jiangsu HengRui Medicine Co., Ltd. · 1 drug in this class
Lahore General Hospital · 1 drug in this class
Mario Negri Institute for Pharmacological Research · 1 drug in this class
Memorial Sloan Kettering Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). LAR Lanreotide — Competitive Intelligence Brief. https://druglandscape.com/ci/lar-lanreotide. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab